NeelimaDenduluriMD, FASCO

Oncology • Arlington, VA

Assistant Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Denduluri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Denduluri's full profile

Already have an account?

Office
1635 N George Mason Dr
Ste 170
Arlington, VA 22205
Phone+1 703-528-7303

Fax+1 703-528-0338

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2007
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1999 - 2002
LSU School of Medicine in ShreveportClass of 1999

Certifications & Licensure

VA State Medical License 1999 - 2026
DC State Medical License 2001 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Not Applicable
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Start of enrollment: 2014 Dec 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Brea...
Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis
Journal of Clinical Oncology. 2024-09-12
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-05-10
3 citations
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-03-27

Lectures

Tailored Therapy for Early-Stage HER2+ Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

The Ongoing Challenge of Pandemic Fatigue Is Hitting People HardJanuary 13th, 2021
Cardiotoxicity in Cancer Tx: LVEF Less Than 55% Is PredictiveJune 17th, 2020
11 Symptoms of Breast Cancer in Women That Aren’t LumpsSeptember 24th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member